Iovance Biotherapeutics, Inc. (IOVA) Stock Price & How to Invest

Iovance Biotherapeutics (Nasdaq: IOVA) develops tumor-infiltrating lymphocyte (TIL) cell therapies, individualized treatments made from a patient's own immune cells. Its lead product, Amtagvi (lifileucel), became the first FDA-approved one-time T-cell therapy for a solid tumor when it was cleared for advanced melanoma, and the company also sells Proleukin, an interleukin-2 product used alongside TIL treatment. Iovance manufactures Amtagvi in-house at its Iovance Cell Therapy Center and has treated more than 1,500 patients across commercial and clinical use, with expanding regulatory approvals including a conditional nod in Australia.

The investment picture is a classic early-commercial biotech: revenue is growing quickly off a small base while the company is still losing money. Full-year 2025 product revenue was roughly $264 million and Iovance guided to about $350 million to $370 million for 2026, driven by Amtagvi adoption and improving gross margins. Against a market capitalization near $1.4 billion, the stock reflects expectations that the ramp continues, manufacturing scale lifts margins, and pipeline programs in lung cancer, endometrial cancer, and other tumors eventually broaden the franchise. The bull case rests on execution; the bear case is dilution, competition, and the operational complexity of individualized cell therapy.

Iovance remains unprofitable and has historically funded operations with stock sales, so ongoing dilution is a real risk to existing shareholders. Amtagvi is a complex, individualized therapy that requires surgery, lymphodepletion, and specialized centers, which can slow adoption and limit the eligible patient pool. Competition from other cell therapies and immuno-oncology approaches, including engineered TIL and CAR-T efforts, could pressure the franchise over time. Manufacturing disruptions, reimbursement hurdles, or clinical setbacks in pipeline programs would materially hurt the growth thesis. As a small-cap biotech, the shares are volatile and sensitive to guidance changes and trial data.

9 analysts publish price targets on IOVA, averaging $8.22 against a $4.07 price as of August 2026, or +102.0%. The published targets run from $4.00 to $14.00, a wide spread, and the ratings split 7 buy, 2 hold, 0 sell. Over the last six months there has been 1 raise and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full IOVA forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Iovance Biotherapeutics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Amtagvi commercial ramp. Amtagvi is the core growth engine, with U.S. The most optimistic published target, $14.00, assumes this works close to its best case.

The case against. Iovance remains unprofitable and has historically funded operations with stock sales, so ongoing dilution is a real risk to existing shareholders. The most pessimistic target, $4.00, is roughly what IOVA is worth if this bites instead.

Read the full bull and bear case on IOVA, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Iovance Biotherapeutics, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$285M
• FY2026 revenue guidance: ~$350M to $370M
• Market cap: ~$1.4B
• Cash (Q1 2026): ~$319M
• Q1 2026 net loss: ~$79M
• Q1 2026 gross margin: ~41%

Iovance trades at roughly five times trailing revenue, a multiple that reflects rapid growth expectations rather than current earnings, since the company is still posting net losses. Losses have been narrowing year over year as Amtagvi revenue scales and margins improve. Valuation ultimately hinges on whether the revenue ramp and margin expansion continue toward eventual profitability.

Other names that sit close to IOVA: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get IOVA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so IOVA sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where IOVA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

IOVA is an execution-driven biotech bet on Amtagvi's ramp and pipeline, priced for growth while the company works toward profitability.

Whether IOVA is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is IOVA a buy or a sell?, and where the stock could go from here in the IOVA stock forecast.

For income investors, whether IOVA pays a dividend and how the payout looks is covered in does IOVA pay a dividend? And to weigh IOVA against a peer, read the full side-by-side comparisons: IOVA vs BMY and IOVA vs CAR.